Fintel reports that on June 18, 2024, Cantor Fitzgerald initiated coverage of Innoviva (NasdaqGS:INVA) with a Overweight recommendation.
Analyst Price Forecast Suggests 0.62% Upside
As of June 12, 2024, the average one-year price target for Innoviva is 16.32. The forecasts range from a low of 16.16 to a high of $16.80. The average price target represents an increase of 0.62% from its latest reported closing price of 16.22.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Innoviva is 267MM, a decrease of 14.27%. The projected annual non-GAAP EPS is 1.29.
What is the Fund Sentiment?
There are 516 funds or institutions reporting positions in Innoviva. This is an increase of 8 owner(s) or 1.57% in the last quarter. Average portfolio weight of all funds dedicated to INVA is 0.18%, an increase of 23.55%. Total shares owned by institutions increased in the last three months by 15.41% to 93,634K shares. 
The put/call ratio of INVA is 1.35, indicating a bearish outlook.
What are Other Shareholders Doing?
Sarissa Capital Management holds 7,277K shares representing 11.65% ownership of the company. No change in the last quarter.
Franklin Resources holds 6,272K shares representing 10.04% ownership of the company. In its prior filing, the firm reported owning 46K shares , representing an increase of 99.27%. The firm increased its portfolio allocation in INVA by 1,427.54% over the last quarter.
Putnam Investments holds 6,270K shares representing 10.04% ownership of the company. In its prior filing, the firm reported owning 6,261K shares , representing an increase of 0.14%. The firm increased its portfolio allocation in INVA by 7.40% over the last quarter.
PHSTX - PUTNAM GLOBAL HEALTH CARE FUND Shares holds 5,139K shares representing 8.23% ownership of the company. In its prior filing, the firm reported owning 5,158K shares , representing a decrease of 0.36%. The firm decreased its portfolio allocation in INVA by 2.00% over the last quarter.
Renaissance Technologies holds 4,365K shares representing 6.99% ownership of the company. In its prior filing, the firm reported owning 272K shares , representing an increase of 93.78%. The firm increased its portfolio allocation in INVA by 6,041.54% over the last quarter.
Innoviva Background Information
(This description is provided by the company.)
Innoviva, Inc. is a healthcare focused asset management company. The Company intends to participate in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva operates in the United States.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
